Balyasny Asset Management Acquires 5.48% Stake in Crescent Biopharma, Inc. (CBIO)

Balyasny Asset Management L.P. (BAM) filed a Schedule 13G on May 15, 2026, disclosing a new 5.48% stake in Crescent Biopharma, Inc. (CBIO). The filing indicates that the reporting persons collectively beneficially own 1,510,033 shares of common stock as of the event date on March 31, 2026. This position is held through Atlas Diversified Master Fund, Ltd. (840,033 shares) and Atlas Private Holdings (Cayman) Ltd. (670,000 shares), for which BAM serves as the investment manager. The reporting group includes BAM, BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny. Each reporting person is deemed to have sole voting and dispositive power over the reported shares. The filing was made pursuant to Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not with the intent to change or influence the control of the issuer. This represents a significant new institutional position for Balyasny Asset Management in the biotechnology firm.